Health Sciences North Research Institute, Sudbury, Ontario, Canada; Laurentian University, Sudbury, Ontario, Canada; Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
Clin Breast Cancer. 2019 Dec;19(6):433-442. doi: 10.1016/j.clbc.2019.05.002. Epub 2019 May 27.
The frequency of circulating leukocytes has been shown to be a prognostic factor in patients being treated for different types of cancer. In breast cancer, tumor-infiltrating leukocytes may predict patient outcome, but few studies have investigated such associations for circulating leukocytes.
Multiparametric flow cytometry was used to examine the immunophenotypes of circulating peripheral blood mononuclear cells for 88 patients with metastatic breast cancer, which was then correlated to breast cancer-specific survival. Patients had been treated either with high-dose cyclophosphamide-containing regimens (group 1, n = 51 patients) or high-dose paclitaxel-containing regimens (group 2, n = 37 patients).
The frequency of peripheral blood CD14 monocytes indicated prognosis for patients in group 1 (but not group 2), while higher levels of CD11c dendritic cells indicated a better prognosis for patients in group 2 (but not group 1). The frequency of a number of different CD4 or CD8 T cell subtypes also predicted prognosis for patients in group 2. For example, patients in group 2 with a higher frequency of circulating CD4 or CD8 naive T cells (CD45RACD95-CD27CD28) showed a poorer prognosis. In contrast, T cells were not associated with prognosis for patients in group 1.
Circulating leukocytes can predict clinical outcome for patients with breast cancer. Prediction of clinical outcome in this cohort of metastatic breast cancer patients was specific to the type of chemotherapy, and this finding is likely to apply to other therapies.
循环白细胞的频率已被证明是治疗不同类型癌症患者的预后因素。在乳腺癌中，肿瘤浸润白细胞可能预测患者的预后，但很少有研究调查循环白细胞的这种关联。
使用多参数流式细胞术检查 88 例转移性乳腺癌患者外周血单个核细胞的免疫表型，然后将其与乳腺癌特异性生存相关联。患者接受了高剂量含环磷酰胺的方案（第 1 组，n=51 例）或高剂量紫杉醇的方案（第 2 组，n=37 例）治疗。
第 1 组患者外周血 CD14 单核细胞的频率提示预后（但第 2 组患者无此提示），而 CD11c 树突状细胞的水平升高提示第 2 组患者的预后较好（但第 1 组患者无此提示）。许多不同的 CD4 或 CD8 T 细胞亚群的频率也预示着第 2 组患者的预后。例如，第 2 组患者循环 CD4 或 CD8 幼稚 T 细胞（CD45RACD95-CD27CD28）频率较高的患者预后较差。相比之下，T 细胞与第 1 组患者的预后无关。
循环白细胞可预测乳腺癌患者的临床结局。在这组转移性乳腺癌患者中，对临床结局的预测与化疗类型有关，这一发现可能适用于其他治疗方法。
